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PoDs differed less than 3.6-fold from PoDs derived from 
in vivo toxicity data for the phenols available in the lit-
erature. Moreover, the in vitro PBK-based reverse dosim-
etry approach could overcome the large disparity that was 
observed previously between the in vitro and the in vivo 
relative potency of the series of phenols. In conclusion, 
this study shows another proof-of-principle that the in vitro 
PBK approach is a promising strategy for non-animal-
based safety assessment of chemicals.
Keywords Physiologically based kinetic (PBK) 
modelling · In vitro–in vivo extrapolation (IVIVE) · 
Alternative for animal testing · Substituted phenols · 
Reverse dosimetry · Embryonic stem cell test (EST)
Introduction
The safety evaluation of chemicals is currently evolving 
from using animal toxicity tests towards the application 
of innovative non-animal based in vitro approaches to pre-
dict toxicity. This development is encouraged by initiatives 
such as the European Registration, Evaluation, Authorisa-
tion and restriction of CHemicals (REACH) (EC 2007), 
the Cosmetic Products Regulation (EC 2009) and the US 
National Research Council report on toxicity testing in the 
twenty-first century (National Research Council 2007). For 
many years, in vitro toxicity assays have been used for haz-
ard identification only, including the detection of genotox-
icity and the ranking and prioritisation of compounds for 
further in vivo toxicity testing (Gülden and Seibert 2005). 
Translation of in vitro data to the in vivo situation is an 
important but limiting step for the use of in vitro outcomes 
in the regulatory risk assessment of chemicals, as toxic-
ity outcomes in vitro derived as such do not always reflect 
Abstract Toxicity outcomes derived in vitro do not 
always reflect in vivo toxicity values, which was previ-
ously observed for a series of phenols tested in the embry-
onic stem cell test (EST). Translation of in vitro data to the 
in vivo situation is therefore an important, but still limiting 
step for the use of in vitro toxicity outcomes in the safety 
assessment of chemicals. The aim of the present study 
was to translate in vitro embryotoxicity data for a series of 
phenols to in vivo developmental toxic potency values for 
the rat by physiologically based kinetic (PBK) modelling-
based reverse dosimetry. To this purpose, PBK models 
were developed for each of the phenols. The models were 
parameterised with in vitro-derived values defining metab-
olism and transport of the compounds across the intestinal 
and placental barrier and with in silico predictions and data 
from the literature. Using PBK-based reverse dosimetry, 
in vitro concentration–response curves from the EST were 
translated into in vivo dose–response curves from which 
points of departure (PoDs) were derived. The predicted 
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in vivo toxicity values (Blaauboer 2010; Punt et al. 2011). 
For example, in our study on the embryotoxic potencies of 
a series of phenols evaluated in vitro with the ES-D3 dif-
ferentiation assay of the embryonic stem cell test (EST), 
it was concluded that the assay did not correctly rank the 
phenols according to their in vivo potency (Strikwold et al. 
2012). In particular, the toxicity of p-heptyloxyphenol was 
relatively higher in the EST than reported in in vivo stud-
ies in the literature as compared to the other phenols tested. 
In the EST, p-heptyloxyphenol displayed a BMC50 that was 
more than three orders of magnitude lower than that of phe-
nol whereas in vivo BMD10 values differed less than three-
fold (Strikwold et al. 2012). Kinetic differences between 
the in vitro and in vivo situation were hypothesised to pro-
vide a reason for the observed disparities (Strikwold et al. 
2012).
Combining in vitro toxicity data with physiologically 
based kinetic (PBK) modelling applying reverse dosim-
etry has recently been shown to provide a promising 
approach to extrapolate in vitro concentration–response 
curves to in vivo dose–response curves from which points 
of departure (PoDs) for the risk assessment of chemicals 
can be derived (Louisse et al. 2010, 2015; Strikwold et al. 
2013). In this way kinetic differences between the vitro 
and in vivo situation can be taken into account and in vivo 
dose–response curves suitable for deriving a PoD for risk 
assessment can be obtained based on in vitro data. How-
ever, as PBK models are generally data intense and their 
development is often time consuming (Loizou and Hogg 
2011), their application is often hampered. Applying in sil-
ico predictions, i.e. quantitative structure–activity relation-
ships (QSARs) and in vitro kinetic experiments may aid the 
development of PBK models by predicting input values for 
kinetic parameters required, thereby also facilitating non-
animal-based safety assessment of chemicals.
For phenol, one of the congeners tested in our previ-
ous in vitro study on the embryotoxic potency of a series 
of phenols (Strikwold et al. 2012), in vitro PBK-based 
reverse dosimetry and subsequently dose–response model-
ling, provided a PoD that appeared to match the range of 
in vivo-derived PoDs (Strikwold et al. 2013). The aim of 
the present study was to translate in vitro embryotoxicity 
data for a series of phenols including p-heptyloxyphenol as 
previously obtained with the EST (Strikwold et al. 2012), 
to in vivo developmental toxicity values for the rat by 
PBK-based reverse dosimetry, using in silico- and in vitro-
defined kinetic parameters. Ultimately, this should elu-
cidate whether combining in vitro data with PBK model-
ling to predict in vivo values can overcome differences that 
were observed between the in vitro and the in vivo relative 
potencies of different phenolic congeners, and especially 
whether this approach can overcome the deviating results 
for p-heptyloxyphenol. This may provide another proof 
of principle to assess the feasibility of this in vitro PBK 




Phenol (99%), p-fluorophenol (99%), p-heptyloxyphenol 
(97%), p-methylketophenol (99%), antipyrine (≥99%), 
fluorescein, Tris(hydroxymethyl)aminomethane (Tris) 
(≥99.9%) and Dulbecco’s modified Eagle’s medium 
(DMEM), uridine 5′-diphosphoglucuronic acid (UDPGA), 
alamethicin (98%), sodium taurocholate hydrate (97%), 
β-glucuronidase (Type 1x-A from Escherichia coli) and 
bovine serum albumin (≥98%) were obtained from Sigma-
Aldrich (Steinheim, Germany). Acetonitrile (ULC/MS 
grade) and methanol (HPLC supra-gradient) were obtained 
from BioSolve (Valkenswaard, the Netherlands), and 
dimethylsulfoxide (DMSO) (≥99%) from Acros Organics 
(Geel, Belgium). Trifluoroacetic acid (TFA), hydrochlo-
ric acid (37%), magnesium chloride hexahydrate, potas-
sium phosphate (≥99%), and Transwell® inserts (0.4 µm 
pored polycarbonate membrane, 12 mm diameter) were 
purchased from VWR International GmbH (Darmstadt, 
Germany). Foetal calf serum (FCS) was purchased from 
HyClone-Perbio (Etten-Leur, the Netherlands). Penicillin, 
streptomycin, l-glutamine, minimal essential medium non-
essential amino acids and trypsin/EDTA in PBS (final con-
centration 0.025/0.01%) were obtained from Gibco (Pais-
ley, Scotland). Phosphate-buffered saline (PBS) and Hank’s 
balanced salt solution (HBSS) were obtained from Invitro-
gen (Breda, the Netherlands) and HEPES was from VWR 
(Radnor, USA).
BeWo choriocarcinoma cells subclone b30 were kindly 
provided by the Institute of Public Health of the Faculty 
of Health Sciences of the University of Copenhagen (Den-
mark) with permission from Dr. Alan Schwartz (Washing-
ton University, St Louis, MO, USA). The provided cell line 
was confirmed to be mycoplasma negative. The colorectal 
adenocarcinoma (Caco-2) cells were obtained from ATCC 
(Middlesex, UK). Pooled liver microsomes from male 
Sprague–Dawley rats were obtained from BD Biosciences 
Gentest (Woburn, MA, USA).
General outline in vitro PBK approach
The in vitro PBK approach to predict in vivo dose–response 
curves and a PoD for risk assessment using in vitro embry-
otoxicity data consisted of the following steps: (1) estab-
lishment of in vitro effective concentrations (ECx) of 
the phenols in the EST, (2) development of PBK models 
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describing in vivo kinetic properties of the phenols in rat 
including derivation of PBK model parameters, (3) sensi-
tivity analysis of the PBK models, (4) translation of in vitro 
ECx values into in vivo external dose levels (EDx) gener-
ating dose–response curves for developmental toxicity in 
rat and enabling the definition of a PoD for risk assess-
ment and (5) evaluation of predictions performed with the 
in vitro PBK approach.
In vitro embryotoxicity
Embryotoxicity data of phenol, p-fluorophenol, p-hepty-
loxyphenol and p-methylketophenol determined using the 
murine embryonic stem cell (ES-D3) differentiation assay 
of the EST by Strikwold et al. (2012) were used as a start-
ing point for the in vitro PBK approach translating in vitro 
embryotoxicity data to in vivo toxicity values. The use of 
both the maximum concentration in foetal plasma (Cmax) 
and the area under the foetal plasma concentration–time 
curve (AUC) in the in vitro PBK approach was evaluated. 
The concentration of phenol and p-fluorophenol decreased 
in time in the EST culture medium (without cells) in a simi-
lar fashion, while p-methylketophenol and p-heptyloxyphe-
nol were stable (Strikwold et al. 2012). Therefore, the AUC 
of the 10-day EST of p-methylketophenol and p-heptyloxy-
phenol was calculated by multiplying the test concentra-
tion by the duration of the experiment (AUC0–10d), while 
the calculated AUC0–10d for phenol and p-fluorophenol was 
reduced by 39% corresponding to the loss of phenol in the 
EST as reported by Strikwold et al. (2013).
Rat PBK model structures for phenols
The rat PBK model for phenol developed by Strikwold 
et al. (2013) was used as a starting point to construct rat 
PBK models for the different phenols of the present study 
(Fig. 1), with four major modifications. The first modifi-
cation is that only liver glucuronidation of the phenolic 
compounds was taken into account in the present study to 
describe the metabolic conversions. This could be done 
because the sensitivity analysis of the previously developed 
PBK model of phenol by Strikwold et al. (2013), performed 
at an oral dose level of 150 mg/kg bw which is consistent 
with high oral dose levels that were applied in in vivo tox-
icity studies of the phenols (Kavlock 1990), identified that 
glucuronidation of phenol in the liver is the most influen-
tial metabolic pathway in the model. Moreover, in vivo 
kinetic studies towards the metabolism of phenol confirm 
the importance of this route, showing that the glucuronide 
conjugate is the predominant metabolite formed at high 
oral dose levels (Hiser et al. 1994). Furthermore, the meta-
bolic parameters Km and Vmax of sulfation were not identi-
fied as a sensitive parameter in the PBK model for phenol 
at high oral dose levels, and the Vmax value for sulfation 
was very low (Strikwold et al. 2013), supporting the choice 
for glucuronidation as the metabolic and elimination path-
way in the current PBK models. A second modification is 
that we have included in vitro transport experiments with 
Caco-2 cells to define the oral uptake constants of the dif-
ferent compounds of the present study, since the previously 
predicted plasma concentrations of phenol appeared to be 
quite sensitive to the oral absorption coefficient (ka). A 
third modification is that a fat compartment was included 
in the PBK models for the different phenolic compounds, 
because p-heptyloxyphenol may readily be distributed 
to adipose tissue due to its relatively high lipophilicity. 
Finally, a placental/foetal compartment was added to the 
PBK models, including transport of the compound from 
the mother to the embryos/foetuses and back by simple 
diffusion. For the placental/foetal compartment, the num-
ber of embryos in one litter was considered to be 12, and 
they were treated as one unit for which the physiological 
parameters were calculated. Foetal–maternal diffusion was 
set equal to maternal–foetal diffusion. To include maternal–
foetal diffusion in the PBK model, apparent permeability 
coefficients (Papp) across placental BeWo cells cultivated in 
a transwell system were derived in vitro and subsequently 
converted to in vivo diffusion transplacental clearance rates 
(l/h; see “In vitro placental transport study” section). The 
Fig. 1  Schematic representation of the PBK models of the phenols
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PBK models were defined with parameters representative 
for gestational day 11 (GD11), facilitating evaluation of the 
PBK model predictions with available in vivo developmen-
tal toxicity data for rats exposed to phenol or p-substituted 
phenol at GD11.
An overview of the PBK model algorithms, which are 
similar for all the phenols, is included in Supplementary 
data A. Kinetic model calculations were performed by 
applying Rosenbrock’s algorithms for solving stiff systems 
(Berkeley Madonna, version 8.3.18, UC Berkeley, CA, 
USA).
PBK model parameter values
Physiological parameters
The physiological parameters used in the PBK model of 
phenol in the rat of Strikwold et al. (2013) were used as 
starting point to define parameters for the pregnant rat at 
GD11. In the PBK models for the phenols, the volume of 
the liver, adipose tissue, uterus, mammary gland, placentas 
and foetuses were estimated by the gestational growth algo-
rithms of O’Flaherty et al. (1992). The uterus and mam-
mary gland were not included as specific compartments in 
the model and the change in volume of these compartments 
was taken into account in the remaining body compartment. 
The volume of the foetuses included also the amniotic fluid 
volume of GD11 that was reported by Park and Shepard 
(1994) and Fisher et al. (1993), because at this gestational 
day maternal–foetal exchange occurs via both the chorio-
allantoic placenta and the yolk sac placenta (Carney et al. 
2004). The volume of the intestine, venous and arterial 
blood was kept similar to values for a non-pregnant rat. The 
total maternal body weight was the sum of the body weight 
of a non-pregnant rat and the placentas and foetuses as well 
as the change of the volume of the liver, adipose tissue, 
uterus and mammary gland during pregnancy.
The total cardiac output and the blood flow to the liver 
for GD11 were obtained from Buelke-Sam et al. (1982a, 
b). The blood flow to the placentas was estimated by the 
gestational growth algorithms of O’Flaherty et al. (1992). 
The blood flow to the adipose tissue was proportional to 
the relative weight of the adipose tissue. The blood flow to 
the small intestine was calculated using reported blood flow 
rates for the specific parts of the splanchnic system of the 
non-pregnant rat by Delp et al. (1998). All physiological 
parameters are presented in Table 1.
In silico predictions of physicochemical and biochemical 
parameters
An overview of physicochemical parameters that are used 
to predict biochemical and distribution parameters of the 
compounds are included in Table 2. Tissue plasma parti-
tion coefficients (Pt:p) were calculated using the algorithm 
of Berezhkovskiy (2004), which requires information on 
plasma protein binding, lipophilicity and acid–base prop-
erties (see Tables 2, 3). The adipose tissue–plasma parti-
tion coefficients were calculated using the olive oil–water 
distribution coefficient (D × vo:wpH7.4), and the partition 
Table 1  Physiological data 
for the rat applied in the PBK 
models of the phenols
a Organ percentages of total maternal body weight at GD11
b Without flow from small intestine
Parameter
Model compartments Percentage of body weighta Percentage of cardiac output
 Small intestine 1.3 5.7
 Liver 3.6 17.3b
 Adipose tissue 7.8 6.3
 Arterial blood 1.8
 Venous blood 5.3
 Placentas 0.30 0.26
 Foetuses and amniotic fluid 0.13
 Body remaining 71.2 70.5
l/h
Cardiac output 7.1
Table 2  Physicochemical properties of the phenols
a Values from ACD/Labs (2015)
b Calculated with Simcyp model (Simcyp 2015)
Parameter Phenol p-Fluoro p-Heptyloxy p-Methylketo
MW (Da)a 94.11 112.10 208.30 136.15
Log Po:wa 1.54 1.84 4.41 1.40
pKaa 9.86 9.92 10.35 8.12
% Ionised in serum 
(pH 7.4)b
0 0 0 16
Arch Toxicol 
1 3
coefficients for the non-adipose tissues were calculated 
with the n-octanol–water partition coefficient (Pow) for the 
non-ionised species at pH 7.4. The value of D × vo:wpH7.4 
was calculated using log Po:w and pKa according to the 
algorithms reported by Poulin and Theil (2002). The 
unbound fraction of the compound in plasma was calcu-
lated with the Simcyp model (Simcyp 2015), after which 
these values were converted to the unbound fraction in tis-
sue using the algorithm of Poulin and Theil (2002). The 
Pt:p values of the placental compartment were set equal 
to the predicted liver–plasma partition coefficient and the 
Pt:p of the embryonic/foetal unit was a volume-weighted 
whole body–plasma partition coefficient, in which the adi-
pose tissue was omitted because of the low amount of fat in 
foetal rat (Sarr et al. 2012). Partitioning of the compounds 
between red blood cells and plasma (Prbc:p) was predicted 
with the algorithms of Paixão et al. (2009) and was sub-
sequently used to calculate the partition coefficient of the 
compounds between blood and plasma (Pb:p) using the fol-
lowing equation:
where HTC corresponds to a hematocrit fraction of 0.45.
In vitro intestinal transport study
Caco-2 cells (passages 37–40) were cultured in DMEM 
containing 25 mM HEPES (pH 7.4) supplemented with 
10% (v/v) heat-inactivated FCS, 4500 mg/l glucose, 
2 mM l-glutamine, 1% (v/v) minimal essential medium 
Pb:p = (Prbc:p× HTC)+ (1− HTC)
non-essential amino acids, 10,000 U/ml penicillin and 
10 mg/ml streptomycin and maintained in polystyrene cell 
culture flasks (Corning, Amsterdam, the Netherlands) in a 
5% CO2-humidified atmosphere at 37 °C. Cells were har-
vested after exposure to a trypsin–EDTA solution. Next, the 
cells were seeded onto Transwell® inserts (0.4 µm pored 
polycarbonate membrane, 12 mm diameter), at a density 
of 105 cells/cm2. Cell culture medium (0.5 and 1.5 ml in 
the apical and basolateral compartment, respectively) was 
changed every two days.
Compounds that were included in the transport experi-
ments were phenol, p-fluorophenol, p-heptyloxyphenol, 
p-methylketophenol, antipyrine (passive transcellular 
control) and fluorescein (passive paracellular control) as 
well as DMSO (solvent control). Stock solutions of the 
test compounds were prepared in DMSO and tested at a 
final DMSO level in the transport buffer of 0.2%, except 
for p-heptyloxyphenol for which the final DMSO level 
was 0.5% due to the relatively lower solubility of this 
compound.
Transport experiments were performed between day 
20 and 23 post-seeding. Prior to the transport experi-
ments, the cell culture medium was removed and cells 
were equilibrated in HBSS for 30–45 min in a 5% CO2-
humidified atmosphere at 37 °C. In these 45 min, the integ-
rity of the cell monolayer was examined by measuring 
the Trans Epithelial Electrical Resistance (TEER) of the 
cell layer using a Millicell ERS-2 Volt–Ohm Meter (Mil-
lipore, USA). Only cell layers with a TEER value between 
500 and 1000 Ω cm2 were used for the transport experi-
ments. The transport buffer for the apical compartment 
consisted of HBSS containing 10 mM HEPES (pH 6.5) 
and 10 mM sodium taurocholate and the transport buffer 
for the basolateral compartment consisted of HBSS (pH 
7.4) with 30 mg/ml bovine serum albumin. At first, 1.5 ml 
pre-warmed (37 °C) transport buffer was added to the baso-
lateral compartment. Then, the transport experiments were 
started by adding 0.5 ml pre-warmed transport buffer con-
taining the test compound (100 µM) to the apical compart-
ment. After 60-min incubation in a 5% CO2-humidified 
atmosphere at 37 °C, a 75 µl sample was taken from the 
basolateral compartment and then from the apical compart-
ment. Each sample was added to 150 µl ice-cold metha-
nol, vortexed and put on ice immediately. The filters of the 
Transwell® inserts were washed one time with HBSS and 
two times with PBS, then cut out from the insert and added 
to 250 µl methanol 65% (v/v) and sonificated for 15 min by 
a Bandelin Sonorex RK100 sonificator (Berlin, Germany). 
Samples were analysed by UPLC–PDA (see “Quantifica-
tion of analytes” section) for the presence of the test com-
pound and possible metabolites.
TEER values were also measured at the end of the 
transport experiment, during the first washing step and 
Table 3  In silico-predicted biochemical and distribution parameters 
of the phenols for the rat
a Fraction unbound to plasma proteins (Fu). Calculated with Simcyp 
model (Simcyp 2015)
b Calculated with algorithms of Berezhkovskiy (2004)
c Assumed to be the same as the partition coefficient of the liver
d Whole body–plasma partition coefficient without adipose tissue 
(volume weighted)
e Calculated with algorithms of Paixão et al. (2009)
Parameter Phenol p-Fluoro p-Heptyloxy p-Methylketo
Fu (pH 7.4; –)a 0.38 0.31 0.03 0.28
Partition coefficientsb
 Liver–plasma 0.81 0.96 7.99 0.64
 Intestine–plasma 0.97 1.20 11.57 0.74
 Adipose–plasma 0.83 1.42 84.38 0.39
 Placenta–plasmac 0.81 0.96 7.99 0.64
 Foetus–foetal 
plasmad
0.76 0.89 6.92 0.61
 Body remaining–
plasma
0.75 0.87 6.67 0.61
 Blood–plasmae 0.72 0.70 1.48 0.67
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compared to the TEER values measured before the trans-
port experiment in order to assess toxicity of the test com-
pound to the cell monolayer. Caco-2 monolayers were 
omitted from further analysis when the TEER value was 
reduced more than 15% during the transport experiments 
(Wang et al. 2014). The Caco-2 transport studies encom-
passed four independently performed experiments includ-
ing three replicates in each assay.
The apparent permeability coefficients (Papp; cm/s) were 
calculated using the following algorithm:
where Papp is the apparent permeability coefficient (cm/s), 
ΔQ/Δt (nmol/s) is the amount of the test compound trans-
ported to the receiver chamber in a certain time period, A 
is the transwell membrane surface area (cm2) and C0 is 
the initial concentration of the test compound in the donor 
compartment (µM).
In order to assess the validity of the Papp calculations for 
this experiment, the linearity of transport from the apical to 
the basolateral side was verified by taking samples from the 
basolateral side at t = 15, 30, 60 and 90 min, at a test con-
centration of 100 µM. The amount of sample (50 µl) with-
drawn from the basolateral side was replaced by a similar 
amount of Caco-2 transport medium, which was accounted 
for in assessing the linearity. The recovery of the test com-
pound in each transport experiment was calculated with a 
mass balance equation, taking into account the amount of 
the test compound in the apical and basolateral compart-
ment and the amount in the cells and/or filter of the Tran-
swell® insert.
To extrapolate the in vitro-derived apparent permeability 
coefficients (Papp) from the Caco-2 transport experiments to 
in vivo oral absorption coefficients (ka), relative Papp ratios 
were calculated with phenol as the standard compound 
(Papp p-substituted phenol/Papp phenol), which were sub-
sequently multiplied by the ka value for phenol of 7.62/h 
obtained from the rat in situ intestinal perfusion study of 
Humphrey et al. (1980).
In vitro placental transport study
BeWo cells (passages 28–31) were cultured in DMEM 
with 4500 mg/ml glucose and supplemented with 10% 
(v/v) heat-inactivated FCS, 2 mM l-glutamine, 10,000 U/
ml penicillin and 10 mg/ml streptomycin and maintained 
in polystyrene cell culture flasks (Corning, Amsterdam, the 
Netherlands) in a 5% CO2-humidified atmosphere at 37 °C. 
Cells were harvested after exposure to a trypsin–EDTA 
solution. Next, the cells were seeded onto Transwell® 





diameter), with a density of 105 cells/cm2. Cell culture 
medium (0.5 and 1.5 ml in the apical and basolateral com-
partment, respectively) was changed daily.
Transport experiments were performed 6 days post-
seeding. The transport buffer consisted of HBSS with 
30 mg/ml bovine serum albumin (apical compartment) and 
10 mg/ml bovine serum albumin (basolateral compartment) 
representing mid- and late gestational maternal and embry-
onic/foetal rat plasma albumin levels, respectively (Honda 
et al. 2008; Mcmullin et al. 2008; Yeoh and Morgan 1974). 
The transport experiments were performed for the same 
compounds and according to the same method as described 
for the Caco-2 transport experiments, except that only cell 
layers with a TEER value >190 Ω cm2 were used for the 
transport experiments. The BeWo transport studies encom-
passed four independently performed experiments includ-
ing two replicates in each assay. Samples were analysed by 
UPLC–PDA (see “Quantification of analytes” section) for 
the presence of the test compound and possible metabo-
lites. The apparent permeability coefficients were calcu-
lated using the same method as described for the Caco-2 
transport experiments.
To extrapolate the in vitro-derived apparent perme-
ability coefficients (Papp) obtained from the BeWo trans-
port experiments to in vivo transplacental clearance rates 
(CLPL), relative Papp ratios were calculated with antipyrine 
as the standard compound [Papp (p-substituted) phenol/Papp 
antipyrine], which were subsequently multiplied by the 
transplacental maternal–foetal antipyrine clearance rate of 
0.18 l/h. This antipyrine clearance rate was obtained by 
converting the reported antipyrine transplacental clearance 
value of 0.448 l/h/kg for the rat at GD20 (Varma and Ram-
akrishnan (1985) to a value for GD11 via allometric scaling 
to maternal body weight (O’Flaherty et al. 1992) using a 
maternal body weight for GD11 reported by Buelke-Sam 
et al. (1982b).
In vitro assays for glucuronidation of phenols by rat tissue
The formation of glucuronide metabolites of the p-sub-
stituted phenols was investigated in incubations with 
rat liver microsomes. Incubation mixtures consisted of 
50 mM Tris–HCl (pH 7.4) and 10 mM MgCl2, contain-
ing (final concentrations) rat liver microsomes (0.2 mg 
protein/ml) and 2 mM UDPGA. To obtain maximum glu-
curonidation activity, the microsomes were activated by 
preincubating the incubation mixture with 0.025 mg/ml 
alamethicin added from a 200 times concentrated stock 
solution in methanol, during 15 min on ice (Fisher et al. 
2000). Subsequently, the incubations were started after 
a 1-min preincubation at 37 °C by addition of the sub-
strate from a 200 times concentrated stock solution in 
DMSO and incubated in a shaking water bath at 37 °C 
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for 45 min. The reactions were terminated by addition of 
ice-cold acetonitrile (20% v/v). In the blank incubation 
mixtures, UDPGA was omitted. Samples were analysed 
by UPLC–PDA (see “Quantification of analytes” sec-
tion). No reference standards of the glucuronide metabo-
lites were commercially available. Hence, the metabolites 
were identified as follows. At first, retention times from 
the UPLC–PDA chromatograms of the parent compound 
of the blank incubation were compared with the reten-
tion times of newly appearing peaks in chromatograms 
of the incubation mixtures, as the glucuronide conjugates 
are expected to elute earlier compared with their parent 
compounds due do their increased hydrophilicity. Sec-
ondly, the formation of the suggested glucuronide conju-
gate was confirmed by enzymatic deglucuronidation with 
β-glucuronidase. For this purpose, a volume of 10 µl of 
the incubation mixture of the glucuronidation assay (that 
was not terminated by the addition of ice-cold acetoni-
trile) was added to 90 µl of 200 mM potassium phosphate 
(pH 6.2). Then, 4 µl of glucuronidase (200 units/ml) was 
added, and the mixtures were incubated for 60 min in a 
shaking water bath at 37 °C. The reactions were termi-
nated by addition of ice-cold acetonitrile (20% v/v) and 
were put on ice. Control samples were treated under the 
same conditions, but without glucuronidase.
After identifying the formation of the glucuronide con-
jugates for the p-substituted phenols, incubations with 
rat liver microsomes were performed to quantify kinetic 
parameters, which are the maximum enzyme reaction rate 
(Vmax) and the Michaelis–Menten constant (Km). The con-
ditions of the incubation assays were optimised to obtain 
linear reaction rates with respect to incubation time and 
protein concentration and non-limiting cofactor levels were 
applied. The optimised incubation mixtures consisted of 
50 mM Tris–HCl (pH 7.4) with 10 mM MgCl2, contain-
ing (final concentrations) 10 mM UDPGA and 0.1, 0.01 
and 0.05 mg microsomal protein/ml for p-fluorophenol, 
p-heptyloxyphenol, and p-methylketophenol, respectively. 
To obtain maximum glucuronidation activity, the micro-
somes were activated by preincubating the incubation mix-
ture with 0.025 mg/ml alamethicin added from a 200 times 
concentrated stock solution in methanol, during 15 min on 
ice (Fisher et al. 2000). Subsequently, the incubations were 
started after a 1-min preincubation at 37 °C by addition of 
the substrate from a 200 times concentrated stock solution 
in DMSO and incubated in a shaking water bath of 37 °C 
for 10 min for p-fluorophenol and 2.5 min for p-heptyloxy-
phenol and p-methylketophenol, respectively. The incuba-
tion experiments encompassed three or four independently 
performed experiments for each phenol.
Kinetic constants for the glucuronidation of the p-substi-
tuted phenols were derived by fitting the data to the stand-
ard Michaelis–Menten equation;
in which [S] represents the substrate concentration, Vmax the 
maximum velocity and Km the Michaelis–Menten constant 
for the formation of the glucuronide metabolites. Data anal-
ysis was accomplished using GraphPad Prism 5.0 software 
(GraphPad, San Diego, CA, USA). For the PBK model, 
the in vitro-derived Vmax values from rat liver microsomes 
were scaled to the in vivo situation using a reported micro-
somal protein yield of 38 mg/g rat liver (Chiu and Ginsberg 
2011). The in vivo Km value was assumed to be the same 
to the in vitro Km value. Michaelis–Menten constants for 
phenol were taken from our previous study (Strikwold et al. 
2013). The present study assumed unrestricted metabolism 
despite the high plasma protein binding of p-heptyloxy-
phenol, because the rapid metabolic turnover is assumed to 
clear the chemical so avidly that protein binding may not 
be rate limiting.
Quantification of analytes
Samples from the BeWo and Caco-2 transport experiments 
were centrifuged at 13,000 rpm at 5 °C for 15 min. Next 
7.5 µl of the supernatant of each sample was analysed by 
UPLC (Waters Acquity). Samples from the glucuronidation 
assays were centrifuged at 15,000 rpm at 5 °C for 5 min. 
Subsequently, 3.5 µl of the supernatant of each sample was 
analysed by UPLC, except for the incubations with p-hep-
tyloxyphenol of which 10 µl was analysed by UPLC. All 
samples, except those from transport studies with fluores-
cein, were analysed on a Waters BEH C18 1.7 µm column, 
2.1 × 50 mm, with nanopure water (0.1% TFA) (A) and 
pure acetonitrile (B) applying a gradient elution. The start 
condition was 100:0 (A:B), changing to 90:10 from 1 to 
2 min, then to 10:90 from 2 to 4 min (or from 2 to 3 min 
when analysing samples for p-heptyloxyphenylglucuron-
ide), remaining at this ratio for 0.5 min and then rapidly 
declining to the start condition. The flow rate was 0.6 ml/
min. Peaks of the analytes were detected with a photodiode 
array detector (PDA, Waters). Analytes, except the glucuro-
nide metabolites, were quantified with a linear calibration 
curve using peak areas obtained at the compounds’ maxi-
mum wavelength. The glucuronide metabolites were, due 
to the absence of commercially available reference com-
pounds, quantified with the calibration curve and at maxi-
mum wavelengths of their parent compound. Differences 
in the UV absorbance between the parent and the glucuro-
nide conjugate at the selected wavelength were quantified 
by comparing the peak areas of the parent compound from 
three different concentrations of the calibration curve with 
the peak areas of corresponding concentrations of the glu-






glucuronidation of the parent compound in a glucuronida-
tion experiment of 2 h. A noticeable difference between 
the peak area of the parent compounds and the glucuronide 
(average of three tested concentrations) was only observed 
for p-fluorophenol (absorbance of conjugate was twofold 
lower compared to the parent), and this difference was used 
to correct the measured absorbance of the parent compound 
from each point of the calibration curve. Fluorescein was 
quantified with a fluorescence SpectraMax M3 microplate 
reader (Molecular Devices, USA) with excitation and emis-
sion at 495 and 538 nm, respectively.
Sensitivity analyses of the PBK models
For each PBK model, a local sensitivity analysis was per-
formed to determine influential parameters. To this pur-
pose, each parameter was changed in turn keeping the other 
ones constant (Chiu et al. 2007). The normalised sensitivity 
coefficient (SC) was calculated using the algorithm:
where C is the initial outcome of the model, which in this 
case is the maximum foetal plasma concentration (Cmax). C′ 
is the output of the model after a 1% parameter change. P 
is the initial parameter value, and P′ is the parameter value 
modified by an increase of 1%. The sensitivity analysis was 
conducted for an oral exposure to a single dose of 2 and 
200 mg/kg bw.
Translation of in vitro effect concentrations in the EST 
to in vivo effect concentrations
In vitro concentration–response data obtained with the EST 
were translated to in vivo dose–response values by applying 
PBK-based reverse modelling, performed as described by 
Strikwold et al. (2013) with some modifications. To correct 
for in vivo and in vitro differences in albumin and fat levels, 
each nominal in vitro effect concentration of p-heptyloxy-
phenol obtained from the EST from Strikwold et al. (2012) 
was translated to an in vivo effect concentration (ECx) 
according to the extrapolation rules of Gülden and Seibert 
(2003). In the extrapolation rule, a value of 0.99 was used 
for the fraction of p-heptyloxyphenol bound to albumin in 
the EST, which was obtained from a reported bound fraction 
of p-heptyloxyphenol in the culture medium of the whole 
embryo culture (WEC) assay (Fisher et al. 1993). In vivo 
albumin and fat levels that are used in the extrapolation rules 
were adjusted to values that correspond to embryos/foetuses 
during mid-/late gestation. An in vivo lipid content of 0.11% 
was applied based on foetal rat data (GD17) presented by 











level of 10 mg/ml was used representing albumin levels in 
mid- and late gestation; GD10 (Yeoh and Morgan 1974) 
and GD18 (Mcmullin et al. 2008). The vitro lipid fraction 
and albumin levels resembling the situation in the EST were 
0.04% and 4.8 mg/ml, respectively (Verwei et al. 2006). For 
the other phenols, no correction according the extrapolation 
rules of Gülden and Seibert (2003) was applied, since it was 
found that in vitro cytotoxicity of phenol tested with the 
fibroblast-like embryonic mouse cell line Balb/c 3T3 clone 
A31 was not affected by differences in bovine serum albu-
min levels reflecting the in vitro and in vivo situation. It is 
assumed that this also applies for p-methylketophenol and 
p-fluorophenol as these compounds have a comparable log 
Po:w value as phenol, which is an important factor in albu-
min binding (Endo and Goss 2011).
Next, the maximum foetal plasma concentrations (Cmax) 
in the PBK model were set equal to the effect concentra-
tions from the EST (which was corrected by the extrapo-
lation rule of Gülden and Seibert (2003) in case of p-hep-
tyloxyphenol). In addition, the foetal plasma AUC in the 
PBK model were set equal to the AUC0–10d from the EST. 
Applying in vitro PBK-based reverse dosimetry, provided 
in vivo effective dose levels (EDx) from which an in vivo 
dose–response curve, and a BMDL05 was derived using the 
Environmental Protection Agency’s Benchmark Dose Soft-
ware (BMDS) version 2.6. For each compound, the bench-
mark dose model selected was the one that provided the 
best fit determined as described by Strikwold et al. (2012).
Evaluation of the data
The BMDL05 predicted with the in vitro PBK approach 
were compared to the BMDL05 (or NOAEL) derived 
from an in literature reported in vivo developmental tox-
icity study with rats that received phenol or p-substituted 
phenol at GD11 Kavlock (1990). The BMDL05 values of 
the in vivo study were derived using the BMDS version 
2.6. For each compound, the benchmark dose model was 
selected that provided the best fit as described by Strik-
wold et al. (2012). In addition, potency ratios were calcu-
lated (potency phenol/potency p-substituted phenol) from 
potency data obtained with the in vitro PBK approach 
(BMDL05), and the in vivo developmental toxicity data 




Phenol and the p-substituted phenols showed a concentra-
tion–response-related inhibition of differentiation of ES-D3 
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cells into beating cardiomyocytes in the EST (Fig. 2) iden-
tifying the embryotoxic potential of the different com-
pounds (Strikwold et al. 2012). The highest difference in 
embryotoxic potential in vitro was observed between phe-
nol and p-heptyloxyphenol, with the BMC50 value being 
three orders of magnitude higher for phenol. The differ-
ences in BMC50 values were much lower between phenol 
and the other p-substituted phenols, including p-fluorophe-
nol and p-methylketophenol, namely 1.9-fold and 4.9-fold, 
respectively (Strikwold et al. 2012).
In silico predictions of biochemical and distribution 
PBK model parameters
Physicochemical parameters that are used for the predic-
tion of PBK model parameters are outlined in Table 2, and 
the predicted biochemical and distribution model param-
eters are presented in Table 3. Notable differences between 
the compounds are the relatively high log Po:w value of 
4.41 for p-heptyloxyphenol compared to log Po:w values 
<1.84 for the other phenols. The tissue–plasma partition 
coefficients of p-heptyloxyphenol are substantially higher 
than those for the other phenols, especially the fat–plasma 
partition coefficient which is 84.4 for p-heptyloxyphenol 
and varies between 0.39 and 1.42 for the other phenols. The 
predicted fraction of phenols unbound to plasma albumin 
differs from 0.03 for p-heptyloxyphenol to 0.38 for phenol.
In vitro intestinal transport study
Each phenol tested in the Caco-2 transport experiment 
showed a linear increase of the test concentration in the 
basal compartment for at least 60 min. The Papp values of 
the Caco-2 experiments are presented in Table 4. Transport 
of each of the test compounds is rapid, and the Papp val-
ues differ at maximum only 1.3-fold between the test com-
pounds, ranging from 51.9 × 10−6 cm/s for p-methylke-
tophenol to 40.2 × 10−6 cm/s for p-heptyloxyphenol. The 
average mass recovery of antipyrine was 93.4%. The mass 
recovery of phenol, p-fluorophenol, p-heptyloxyphenol and 
p-methylketophenol was on average 80.2, 78.2, 70.4 and 
82.1%, respectively.
In vitro placental transport study
Each phenol tested in the BeWo transport experiment 
showed a linear increase in concentration in the basal 
compartment for at least 60 min, after addition of the test 
compound to the apical side (final concentrations apical 
compartment 100 and 500 µM). The mass balances showed 
that >90% of the mass of each compound was conserved 
in each transport experiment. The Papp values are presented 
in Table 4. Transport is rapid for each of the compounds, 
except for p-heptyloxyphenol which showed a Papp value 
of 5.9 × 10−6 cm/s, which is 6.8-fold lower than the Papp 
value of antipyrine. The Papp values for the other phenols 
were comparable to antipyrine, showing a 1.03-fold higher 
Fig. 2  Concentration–response curves for phenol (grey line, open 
square), p-fluorophenol (solid line, cross symbol), p-heptyloxyphenol 
(dashed line, filled circle) and p-methylketophenol (dotted line, filled 
down pointing triangle) representing the inhibition of differentiation 
of the embryoid bodies (EBs) by the compound. Data obtained from 
Strikwold et al. (2012)
Table 4  Mean apparent 
permeability (Papp ± SD) 
obtained from Caco-2 and 
BeWo transport assays, 
predicted intestinal oral 
absorption coefficients (ka) 
and predicted rat transplacental 
clearance values (CLPL) for the 
test compounds
a Predicted oral absorption coefficient (see “Materials and methods” section)
b Uptake rate from in situ intestinal perfusion study in rat (Humphrey et al. 1980)
c Predicted rat transplacental clearance (see “Materials and methods” section)
d Transplacental clearance value obtained from in vivo rat study (Varma and Ramakrishnan 1985). (see 
“Materials and methods” section)
Compound Papp_Caco-2 (10
−6 cm/s) kaa (/h) Papp_BeWo (10
−6 cm/s) CLPLc (l/h)
Phenol 48.4 ± 8.6 7.62b 41.6 ± 3.4 0.19
p-Fluorophenol 47.7 ± 13.8 7.52 34.2 ± 3.3 0.15
p-Heptyloxyphenol 40.2 ± 3.9 6.34 5.9 ± 1.7 0.026
p-Methylketophenol 51.9 ± 6.6 8.18 27.5 ± 1.7 0.12
Antipyrine 42.7 ± 2.6 6.73 40.4 ± 3.2 0.18d
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and 1.2- and 1.5-fold lower Papp value compared to the 
value of the reference compound antipyrine for phenol, 
p-fluorophenol and p-methylketophenol, respectively. The 
transport of the paracellular control fluorescein was on 
average 11-fold lower compared to the passive transcellular 
control antipyrine indicating the integrity of the monolayer.
An interesting observation was that the Papp value for 
p-heptyloxyphenol obtained from the BeWo experiment 
was 6.8-fold lower than the Papp value from the Caco-2 
experiment, while the Papp values for the other phenols 
were less than twofold lower in the BeWo assay, and 
the Papp value from the BeWo experiment for antipyrine 
was only 1.1-fold lower than the Papp from the Caco-2 
experiment.
In vitro glucuronidation of p‑substituted phenols by rat 
liver microsomes
Results from the incubation experiments showed that rat 
liver microsomes were able to metabolise the p-substituted 
phenols to their glucuronide conjugates. Metabolism of the 
p-substituted phenols followed Michaelis–Menten kinetics 
(Fig. 3). The apparent Km and Vmax values of the rat liver 
microsomes and the (scaled) catalytic efficiencies are pre-
sented in Table 5. The compound p-heptyloxyphenol was 
far more efficiently converted by liver microsomes than the 
other phenols. The scaled catalytic efficiency (l/h/g liver) 
for glucuronidation of p-heptyloxyphenol was 145-fold 
higher than that of phenol. The scaled catalytic efficiencies 
of p-fluorophenol and p-methylketophenol were respec-
tively 1.7-fold and sixfold higher than that of phenol. 
Sensitivity analysis
The results of the sensitivity analysis performed at a high 
oral dose of 200 mg/kg bw (Fig. 4) indicated that the most 
influential parameters for the phenol models are the body 
weight, cardiac output, volume of the liver, parameters 
related to glucuronidation in the liver (Vmax, Km and liver 
microsomal protein yield), the oral absorption coefficient 
and the partition blood-plasma coefficient. The parameter 
Km was of higher influence in the models of p-methylke-
tophenol and p-heptyloxyphenol than in the other phenol 
models. In the model for p-heptyloxyphenol, the cardiac 
Fig. 3  Concentration-dependent formation of the glucuronide conju-
gate of phenol (filled diamond), p-fluorophenol (filled down pointing 
triangle), p-methylketophenol (filled square) (a) and p-heptyloxyphe-
nol (filled circle) (b) in incubations with rat liver microsomes. Indi-
vidual symbols represent mean activities of 3–4 independently per-
formed experiments ±SD
Table 5  Kinetic constants Km and Vmax ± SD, and catalytic efficiencies of the formation of the glucuronide metabolite of the phenols in rat liver 
microsomes
a µM
b nmol/min/mg microsomal protein
c Vmax/Km (ml/min/mg protein in rat liver microsomes)
d µmol/h/g liver
e l/h/g liver
Compound Km(app)a Vmax(app)b Catalytic efficiency
c Scaled Vmax(app)d Scaled catalytic efficiency
e
Phenol 465 ± 66 90 ± 4 0.19 205 0.44
p-Fluorophenol 314 ± 16 101 ± 1.6 0.32 231 0.74
p-Heptyloxyphenol 2.1 ± 0.6 60 ± 4.5 28.0 137 63.8
p-Methylketophenol 138 ± 17 160 ± 4.4 1.16 365 2.65
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output and parameters related to the intestine (volume 
intestine, flow to intestine and partition coefficient intes-
tinal tissue–plasma) are more influential than in the mod-
els of the other phenols. Parameters related to the foetal/
placental compartment do not highly influence the model 
outcome.
In general, the model outcomes are sensitive to similar 
parameters at a low oral dose of 2 mg/kg bw when com-
pared to the analysis at 200 mg/kg bw. Parameters related 
to the intestine in the model for p-heptyloxyphenol are 
not of influence at a low dose of 2 mg/kg bw. Moreover, 
the values of sensitivity coefficients of the phenols for ka, 
body weight and volume of the liver, derived at a low dose 
of 2 mg/kg bw, are lower than the sensitivity coefficients 
derived at 200 mg/kg bw. The sensitivity coefficients for 
the microsomal protein content and the Vmax for glucuro-
nidation in the liver for p-fluorophenol, p-heptyloxyphe-
nol and p-methylketophenol are lower than the sensitivity 
coefficients for these parameters derived at 200 mg/kg bw, 
while the sensitivity coefficients for phenol and p-fluoro-
phenol for Km are higher when compared to the sensitivity 
coefficients derived at 200 mg/kg bw.
Translation of in vitro effect concentrations in the EST 
to in vivo dose levels
In a first step the in vitro concentrations of p-heptyloxy-
phenol were converted to equivalent plasma concen-
trations using extrapolation rules of Gülden and Seib-
ert (2003). Only a very small difference was observed 
between the in vitro effect concentrations from the EST 
and the estimated equivalent plasma concentrations, with 
the latter being 2.1-fold higher than the in vitro effect con-
centrations. In a second step, the in vivo effect concen-
trations were translated to external in vivo oral dose val-
ues using the PBK models thus defining a dose–response 
curve from which a PoD could be derived. The predicted 
dose–response curves based on Cmax or the AUC0–10d are 
presented in Fig. 5. The BMDL05 values for the phenols 
predicted by the in vitro PBK approach using Cmax and the 
AUC0–10d from the EST as a dose metric for reverse dosim-
etry are outlined in Table 6, together with the BMDL05 val-
ues that were predicted from in vivo developmental toxic-
ity data reported in the literature. The in vivo experimental 
data and the PBK model-based predictions were represent-
ative for exposure at GD11 since in the in vivo experimen-
tal study exposure was at GD11 and for the predictions the 
PBK model was defined using physiological parameters 
representative for GD11. Comparing the BMDL05 values 
that were predicted with the in vitro PBK approach with 
the BMDL05 values derived from in vivo data indicates that 
the BMDL05 that is based on Cmax as a dose metric repre-
sents the in vivo BMDL05 better than the BMDL05 based 
on the AUC0–10d for phenol and p-fluorophenol, while for 
p-methylketophenol both the BMDL05 based on Cmax and 
AUC0–10d seem to represent the in vivo BMDL05 well. The 
difference between the BMDL05 values predicted with 
the in vitro PBK approach based on Cmax of the EST as a 
dose metric and the BMDL05 values obtained with in vivo 
developmental toxicity data vary less than 3.6-fold for 
these three phenols. For p-heptyloxyphenol, however, the 
BMDL05 value based on AUC0–10d of the EST as a dose 
Fig. 4  Normalised sensitivity coefficients for parameters of the 
PBK model for phenol (white bars), p-fluorophenol (dark grey bars), 
p-heptyloxyphenol (black bars) and p-methylketophenol (light grey 
bars) based on foetal Cmax values from a single oral dose of 2.0 mg/
kg bw (a) and 200 mg/kg bw (b). Normalised sensitivity coefficients 
≥0.2 are presented. BW body weight, VIc fraction intestinal tissue, 
VL fraction liver tissue, VPL volume placental tissue, QC cardiac 
output, QIc fraction intestinal flow, QLc fractional liver flow, QPLc 
fractional placental flow, PI:P partition coefficient intestine:plasma, 
PPL:P partition coefficient placenta:plasma, PB:P partition coef-
ficient body remaining:plasma, PBL:P partition coefficient 
blood:plasma, ka oral absorption coefficient, MPL liver microsomal 
protein yield, VmaxLPGc unscaled maximum rate of glucuronidation 
of phenols in liver, KmLPG Michaelis–Menten constant for glucuro-
nidation of phenols in liver
 Arch Toxicol
1 3
metric represents the in vivo BMDL05 somewhat better 
(1.7-fold difference) than the predicted BMDL05 based on 
Cmax (4.2-fold difference).
The potency ratios between phenol and p-fluorophenol, 
p-heptyloxyphenol and p-methylketophenol calculated 
based on the BMDL05 values obtained with the in vitro 
PBK approach are graphically presented in Fig. 6, together 
with the potency ratios obtained from the in vivo devel-
opmental toxicity study of Kavlock (1990) and the EST. 
The difference between the most and the least potent test 
compound in the EST, p-heptyloxyphenol and phenol 
was three orders of magnitude (Strikwold et al. 2012), 
which does not reflect the potency ratio obtained from the 
in vivo developmental toxicity study which shows a small 
potency difference between the phenols (maximum 0.5-
fold for the potency ratio based on the in vivo BMDL05 
or NOAEL). From Fig. 6, it can be seen that the large dif-
ference in the toxic potency that was observed in the EST 
for p-heptyloxyphenol compared to phenol was greatly 
diminished, namely from 1553-fold in the EST to 0.8-
fold in the in vitro PBK approach when based on the Cmax. 
The potency ratio between phenol and p-fluorophenol and 
p-methylketophenol was changed from 1.9- to 0.7-fold and 
from 4.9- to 0.5-fold, respectively.
Discussion and conclusion
Translation of in vitro toxicity data to in vivo toxicity val-
ues is highly relevant in order to use in vitro data in the 
regulatory risk assessment of chemicals. In previous stud-
ies it was demonstrated that PBK-based reverse dosimetry 
converting in vitro concentration–response values to in vivo 
dose–response data could successfully be applied to predict 
a PoD for phenol (Strikwold et al. 2013), for all-trans-reti-
noic-acid (Louisse et al. 2015) and for some glycol-ethers 
(Louisse et al. 2010). The aim of the present study was to 
investigate whether PBK-based reverse dosimetry could 
Fig. 5  In vivo dose–response curves for developmental toxicity of 
phenol (solid black line), p-fluorophenol (solid grey line), p-hepty-
loxyphenol (dashed line) and p-methylketophenol (dotted line) in rat 
predicted by in vitro PBK-based reverse dosimetry. a Represents the 
predicted dose–response curves based on the nominal test concentra-
tion of the phenols relating Cmax to developmental toxicity. b Repre-
sents the predicted dose–response curves relating the AUC0–10d of the 
phenols to developmental toxicity
Table 6  BMDL05 values (mg/kg bw) for developmental toxicity of 
the phenols predicted with the in vitro PBK approach and BMDL05 
values derived from in vivo developmental toxicity data reported in 
the literature
a Derived from in vivo developmental toxicity data (most critical 
endpoint) from Kavlock (1990)
Compound In vitro PBK approach In vivo
BMDL05_Cmax BMDL05_AUC BMDL05 (or 
NOAEL)a
Phenol 92 1603 333
p-Fluoro 135 1939 183
p-Heptyloxy 115 281 484


















Fig. 6  Potency of p-substituted phenols relative to phenol expressed 
as a potency ratio (potency ratio = potency phenol/potency p-sub-
stituted phenol), specified for the in vitro PBK approach (BMDL05) 
using Cmax as dose metric, the in vivo data (most critical endpoint) 
from Kavlock (1990) (BMDL05 or NOAEL) and the EST (BMC50)
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be used to translate in vitro embryotoxicity data obtained 
with the EST for a series of phenols (Strikwold et al. 
2012) to in vivo developmental toxic potency values for 
the rat, using only in silico- and in vitro-derived (kinetic) 
parameters and data from the literature, and whether this 
approach could overcome differences in in vitro and in vivo 
relative potencies of different phenolic congeners observed 
by Strikwold et al. (2012). The PoDs predicted with the 
in vitro PBK approach differed only 3.6-fold from the 
PoDs derived from in vivo data from literature, when Cmax 
of the EST was considered to be the most appropriate dose 
metric for in vitro PBK-based reverse dosimetry for phenol 
and p-fluorophenol and the AUC0–10d for p-heptyloxyphe-
nol, while both Cmax and AUC0–10d were appropriate met-
rics for p-methylketophenol. The large difference between 
the in vitro-derived relative potency and the in vivo-derived 
relative potency of p-heptyloxyphenol was reduced from 
three orders of magnitude for the EST data as such (Strik-
wold et al. 2012) to <2.1-fold after applying PBK-based 
reverse dosimetry to these EST data.
Results from our in silico- and in vitro-derived (kinetic) 
parameters together with PBK modelling provide insight 
into the possible factors underlying the relative low toxic 
potency for p-heptyloxyphenol in vivo (Kavlock 1990) com-
pared to the relatively high observed embryotoxic potency 
in vitro in the EST (Strikwold et al. 2012). This discrepancy 
may be due to three major factors that play a role in vivo but 
not in the EST in vitro model, including (1) the relatively 
rapid metabolism of p-heptyloxyphenol by glucuronidation, 
(2) the relatively low placental transport of p-heptyloxyphe-
nol compared to the other phenols and (3) the relatively high 
tissue-plasma partition coefficients of p-heptyloxyphenol. 
Of these three aspects, the rapid glucuronidation of the toxic 
parent compound p-heptyloxyphenol has the largest contri-
bution to the improved relative potency prediction for this 
compound. The contribution of metabolism in diminishing 
the toxicity of p-heptyloxyphenol was also observed in the 
WEC assay where the embryotoxic potency of p-heptyloxy-
phenol was greatly reduced when hepatocytes were added 
to the WEC assay (Oglesby et al. 1992).
The affinity constant Km for glucuronidation of the 
phenols in the liver was found to be an influential kinetic 
parameter in the sensitivity analysis. The Km of p-hepty-
loxyphenol was much lower than the Km of the other tested 
phenols, resulting in a very rapid glucuronidation and elim-
ination of the toxic parent compound. The high lipophilic-
ity of p-heptyloxyphenol may explain the high affinity for 
the enzyme.
Transport across the placenta was determined with the 
BeWo cell line, and provided high Papp values for each of 
the test compound, except for p-heptyloxyphenol for which 
the Papp value was 7.1-fold lower compared with phenol. 
The high Papp values are in line with in vivo studies in rats 
reporting that simple phenolic compounds may readily 
pass the placenta (Abu-Qare et al. 2000; Gray and Kav-
lock 1990). In general, cellular permeability increases with 
increasing lipophilicity, until a certain threshold (Water-
house 2003; Wils et al. 1994). It has been demonstrated 
in vitro with intestinal cells that transport may decrease for 
compounds with an octanol–buffer distribution coefficient 
>3000 (Wils et al. 1994), which corresponds to our obser-
vations for p-heptyloxyphenol [logP:ow = 25,704 (ACD/
Labs 2015)] in the Caco-2 and the BeWo assays. Interest-
ingly, the Papp value of p-heptyloxyphenol in the BeWo 
transport experiment was 7.1-fold lower than the Papp value 
of phenol while this was only 1.2-fold in the Caco-2 assay. 
The observed difference may be due to binding of p-hepty-
loxyphenol to albumin that is present in the apical medium 
of the BeWo assay but not in the apical medium of Caco-2 
assay. These albumin levels were selected to reflect physi-
ological conditions. The predicted Papp value in the BeWo 
assay for p-heptyloxyphenol may be somewhat lower than 
the in vivo value, as Li et al. (2013) observed that the rela-
tive Papp value of the highly albumin bound compound 
ketoprofen was 3.4-fold lower in the BeWo system with 
albumin, compared to the relative Papp determined with the 
ex vivo perfusion system that also included albumin. This 
difference possibly originates from differences in the fluid 
dynamics of both systems, which was static in the BeWo 
assay and is dynamic in the ex vivo perfusion system (Li 
et al. 2013).
Incorporating permeability data obtained from the BeWo 
transport system to semi-quantitatively predict placental 
transfer in the PBK models in the present study presents 
an approach that has not been applied in PBK modelling 
before. The BeWo transport system was evaluated to be a 
valuable in vitro model to predict transport of compounds 
across the placenta (Li et al. 2013). Nonetheless, this 
approach may be explored further, investigating the appli-
cability domain of the BeWo assay with respect to different 
chemical classes, i.e. lipophilic compounds, as well as the 
time of pregnancy to augment its utility.
The present study predicted the embryotoxic potency 
of the phenols with physiological parameters in the PBK 
model selected for GD11 because for this time point 
in vivo developmental toxicity data for evaluation of the 
predictions were available. The EST was used to represent 
a sensitive in vitro endpoint for developmental toxicity 
(Genschow et al. 2004), which ideally may represent the 
sensitivity of the embryo at the critical window for toxicity 
of the p-substituted phenols. Parameterisation of the PBK 
model for other gestational days is possible. Calculations 
with parameters adjusted to GD20 (data not shown) indi-
cate little differences with GD11, providing a 1.2- to 2.3-
fold higher BMDL05 value for predictions made with the 
PBK parameters for GD20 than for GD11 for the different 
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phenols. Based on these results, the predictions for GD11 
may be regarded to represent a sensitive period.
In our study we extrapolated each nominal effective 
concentration tested in the EST to an in vivo effective dose 
value using PBK-based reverse dosimetry, from which 
an in vivo dose–response curve and BMDL05 values were 
derived with the BMDS software. Sometimes only a single 
BMCx is available (often a BMC50) and extrapolating this 
single BMC50 to a BMD50 with reverse dosimetry will likely 
result in almost similar BMD50 values as would be obtained 
with our approach when kinetics are linear, but may deviate 
to a larger extent in case of nonlinear kinetics. Moreover, 
extrapolating just the BMC50 value to a BMD50 value may 
bring other difficulties as we cannot extrapolate this value 
easily to a PoD that would be relevant for the risk assess-
ment, like a BMDL05 or BMDL10. Therefore in our study, 
we extrapolated each nominal effective concentration to an 
in vivo effective dose value as described above.
In conclusion, PBK models were developed for a series 
of phenols, using in vitro, in silico data and data obtained 
from the literature only. Applying the in vitro PBK-based 
reverse dosimetry approach to overcome kinetic differences 
between the in vitro toxicity test system and the in vivo 
situation resulted in an improved prediction of the in vivo 
developmental toxic potency for this series of phenols. 
This approach has even overcome the large disparities that 
were observed between the in vitro and the in vivo rela-
tive potencies of p-heptyloxyphenol. Herewith, we provide 
another proof of principle that integrating in vitro toxicity 
data and PBK-based reverse dosimetry may be a promising 
approach for prospective toxicological safety evaluations of 
compounds, without performing animal testing.
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